Rx (Prescription Medicine)
USD $ 120.00
Vegfxta 100mg注射液是一种靶向疗法，用于治疗某些类型的癌症。其活性成分被认为是Bevacizumab，一种重组人源化单克隆抗体。Bevacizumab通过抑制血管内皮生长因子（VEGF），从而阻止新血管的生长。通过阻断VEGF，Vegfxta有助于使肿瘤缺乏血液供应，从而减缓或停止其生长。它适用于特定的转移性癌症的治疗，通常与化疗联合使用。Vegfxta 100mg注射液的剂量和给药方式应由合格的医疗专业人员根据患者的病情和治疗反应来确定。常见的不良反应可能包括高血压、蛋白尿、鼻出血和疲劳。严重的不良反应可能发生，患者应密切监测。Vegfxta 100mg注射液应储存在室温并避光保存。对于任何不良反应，务必咨询医生以获得正确的诊断、治疗和管理。
| Medicine Form | |
|---|---|
| Rx Status | |
| Medicine Type | |
| Molecule | |
| Strength |
其他品牌的 Bevacizumab 100 Mg — 同一活性成分且强度相同，但来自不同制造商。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
